Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0GE2F
|
||||
| Former ID |
DIB000354
|
||||
| Drug Name |
GSK-2485852
|
||||
| Synonyms |
GL-60667; GSK-2485852A; NVP-LDI133; HCV RNA polymerase inhibitors, Genelabs/Novartis; NS5b non-nucleoside inhibitors (HCV infection), GSK/Novartis; NS5b non-nucleoside inhibitors (HCV), Genelabs/Novartis
|
||||
| Indication | HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10:B17.1, B18.2] | Terminated | [1] | ||
| Company |
Genelabs Technologies Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Hepatitis C virus NS5B polymerase | Target Info | Inhibitor | [2] | |
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024593) | ||||
| REF 2 | In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2013 Nov;57(11):5216-24. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.